Welcome to our dedicated page for Liquidia Corporation SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Liquidia Corporation filings document a Delaware biopharmaceutical issuer reporting on YUTREPIA commercialization, treprostinil products and pulmonary hypertension programs. Form 8-K reports furnish quarterly and annual financial results, Regulation FD disclosures, corporate updates and investor presentation materials tied to PAH, PH-ILD, PRINT® Technology and the company’s product portfolio.
The filing record also covers governance and capital-market disclosure subjects, including definitive proxy materials, officer appointments and material definitive agreements. Recent agreement disclosures include the Liquidia Technologies licensing arrangement with Vectura for L606 and a nebulizer device in hypertension and interstitial lung disease treatment fields.
Liquidia Corporation received an amended Schedule 13G/A from a group of Farallon investment funds and related entities reporting significant passive ownership of its common stock. Several Farallon entities report beneficial ownership stakes, including 8,656,038 Shares, or 9.9% of the class, for certain Farallon individual reporting persons.
The amendment mainly updates who at Farallon is treated as a beneficial owner. Effective December 31, 2025, Richard B. Fried, Rajiv A. Patel, and William Seybold ceased to be deemed beneficial owners. Effective January 1, 2026, Avner A. Husen became a member/manager of Farallon’s general partner entities and may be deemed a beneficial owner. The filing certifies the holdings are not for changing or influencing control of Liquidia.
Liquidia Corp’s Chief Accounting Officer, Dana Boyle, reported a small automatic share sale. On January 26, 2026, she sold 1,580 shares of common stock at $41.65 per share in a transaction coded “S.”
The sale was effected under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2023 and was used to cover taxes tied to the settlement of restricted stock units granted on January 25, 2023. After this transaction, Boyle beneficially owns 178,848 shares, including multiple blocks of unvested RSUs and 3,527 shares acquired through the 2020 Employee Stock Purchase Plan.
Liquidia Corp’s Chief Business Officer, Jason Adair, reported a small, pre-planned stock sale. On January 26, 2026, he sold 688 shares of common stock at $41.65 per share under a Rule 10b5-1 trading plan to cover taxes from restricted stock unit (RSU) settlement.
After this sale, Adair beneficially owned 211,169 shares, including multiple blocks of unvested RSUs granted between 2023 and 2026 and 11,586 shares acquired under Liquidia’s 2020 Employee Stock Purchase Plan. The transaction reflects routine tax-related activity rather than a large discretionary sale.
Liquidia Corp’s Chief Business Officer, Jason Adair, reported new equity awards. On January 16, 2026, he was granted 27,683 restricted stock units (RSUs) that convert into common stock on a one-for-one basis. These RSUs vest with 25% on January 11, 2027 and 6.25% every three months thereafter.
On the same date, he was also granted 41,525 performance stock units (PSUs), which also convert into common stock one-for-one. The PSUs follow a similar time-based vesting schedule tied to the Initial Vesting Date or the filing of the company’s Form 10-K for the year ending December 31, 2026, and include a milestone condition based on 2026 net product sales revenue from YUTREPIA. After these transactions, Adair beneficially owned 211,857 shares of common stock and 41,525 PSUs, all held directly.
Liquidia Corp’s Chief Accounting Officer, Dana Boyle, reported new equity awards on a Form 4. On January 16, 2026, Boyle received 23,728 restricted stock units (RSUs) of Liquidia common stock at a price of $0, bringing directly owned common stock (including unvested RSUs and ESPP shares) to 180,428 shares after the transaction. RSUs convert into common shares on a one-for-one basis and follow a vesting schedule where 25% vests on January 11, 2027, with 6.25% vesting every three months thereafter.
Boyle was also granted 35,592 performance stock units (PSUs) on the same date, also at $0 per unit. PSUs convert into common stock on a one-for-one basis and vest over time, starting with 25% on the same initial vesting date (or when the company files its Form 10-K for the year ending December 31, 2026, if later), and 6.25% every three months after that. Vesting of these PSUs depends on a milestone tied to 2026 net product sales revenue from YUTREPIA as disclosed in Liquidia’s FY2026 Form 10-K.
Liquidia Corp Chief Executive Officer and director Roger Jeffs reported new stock-based awards and updated his holdings. On January 16, 2026, he received 115,344 shares of common stock for $0, representing restricted stock units that convert one-for-one into common shares. On the same date, he was granted 173,016 performance stock units, also at $0, each convertible into one share of common stock.
The RSUs vest with 25% on January 11, 2027 and 6.25% every three months afterward. The PSUs follow a similar time-based schedule but vest only if a milestone is met, based on the percentage of units tied to 2026 net product sales revenue from YUTREPIA as disclosed in the company’s FY2026 Form 10-K. After these grants, Jeffs directly owns 1,152,872 common shares, with additional indirect holdings through a living trust and Serendipity BioPharma LLC.
Liquidia Corp insider Michael Kaseta, the CFO and COO, reported new equity awards. On January 16, 2026, he received 59,320 shares of common stock in the form of restricted stock units granted at $0 per share, bringing his directly held common stock to 410,239 shares. These RSUs convert into common stock on a one-for-one basis and vest over time, with 25% vesting on January 11, 2027 and the remainder vesting quarterly thereafter.
Kaseta was also granted 88,980 performance stock units at $0 per unit, each linked to one share of common stock. These PSUs vest on a similar time schedule, but only if a milestone is met based on 2026 net product sales revenue from YUTREPIA as disclosed in Liquidia’s Form 10-K for the year ending December 31, 2026. This structure ties a significant portion of his potential equity compensation to both continued service and specific revenue performance.
Liquidia Corp’s Chief Development Officer, Sanjeev Khindri, reported a stock-based award related to 34,274 shares of common stock on January 16, 2026. These shares reflect restricted stock units (RSUs) that convert into common stock on a one-for-one basis at no cash cost to him.
According to the filing, 71,266 shares of common stock are beneficially owned following this transaction, consisting entirely of unvested RSUs. The vesting schedule states that 25% of the RSUs vest on January 11, 2027, with an additional 6.25% vesting every three months thereafter.
Liquidia Corp Chief Human Resource Officer Sarah Krepp received new equity awards that increase her stake in the company. On January 16, 2026, she was granted 23,728 restricted stock units (RSUs) that convert into common stock on a one-for-one basis at no cash cost. After this grant, she beneficially owns 164,497 shares of common stock, including previously granted unvested RSUs and shares acquired under the employee stock purchase plan.
On the same date, she was also granted 35,592 performance stock units (PSUs), which also convert into common stock one-for-one and were reported at a price of $0. Both the RSUs and PSUs follow a similar time-based schedule in which 25% vest on January 11, 2027 (or, for PSUs, potentially when the company files its Form 10-K for 2026) and 6.25% vest every three months thereafter, with the PSUs additionally requiring a milestone based on 2026 net product sales revenue from YUTREPIA.
Liquidia Corp’s Chief Commercial Officer, Scott Moomaw, reported new equity awards. On January 16, 2026, he received 32,955 shares of common stock in the form of restricted stock units (RSUs) at $0 per share, which convert into common stock on a one-for-one basis and vest 25% on January 11, 2027, with 6.25% vesting every three months thereafter. After this grant, he directly beneficially owned 187,469 shares of common stock, including multiple prior RSU grants and shares from the employee stock purchase plan. He was also granted 49,433 performance stock units (PSUs), which convert one-for-one into common stock and vest over time starting on the initial vesting date or the filing of the company’s Form 10-K for 2026, subject to a milestone based on 2026 net product sales revenue from YUTREPIA.